Gilead Sciences

Gilead Sciences, founded in 1987, is a leading biopharmaceutical company committed to advancing innovative medicines to prevent and treat life-threatening diseases. Headquartered in Foster City, California, Gilead has established itself as a global leader in the healthcare industry, driven by a relentless pursuit of scientific excellence and a commitment to improving patient outcomes.

Under the leadership of CEO Daniel O’Day, Gilead focuses on delivering transformative therapies in areas of unmet medical need, including viral diseases, liver diseases, and cardiovascular conditions. The company's portfolio includes groundbreaking treatments for HIV/AIDS, hepatitis B and C, and various cancers. With a workforce of approximately 18,000 employees, Gilead continues to drive innovation and expand its impact on global health.

Gilead's dedication to research and development has led to numerous medical advancements, significantly improving the lives of patients worldwide. The company collaborates with healthcare professionals, organisations, and communities to ensure access to its life-saving treatments. As a forward-thinking biopharma leader, Gilead remains committed to making a lasting difference in the lives of those affected by serious illnesses.